LY3461767 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Heart Failure With Reduced Ejection Fraction
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Trial Timeline
Jun 1, 2021 → May 9, 2024
NCT ID
NCT04840914About LY3461767 + Placebo
LY3461767 + Placebo is a phase 1 stage product being developed by Eli Lilly for Chronic Heart Failure With Reduced Ejection Fraction. The current trial status is completed. This product is registered under clinical trial identifier NCT04840914. Target conditions include Chronic Heart Failure With Reduced Ejection Fraction.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04840914 | Phase 1 | Completed |
Competing Products
20 competing products in Chronic Heart Failure With Reduced Ejection Fraction